Trial Profile
A phase 2 study of IMC-A12 (NSC742460) in hepatocellular carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Cixutumumab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 23 Feb 2011 Actual end date (February 2011) added as reported by ClinicalTrials.gov.
- 23 Feb 2011 Status changed from suspended to completed as reported by ClinicalTrials.gov.
- 12 Jun 2009 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.